Skip to main content

Pharmatica — home

Insights
Topics
Interviews
Council
Services
- Sentinel
- Vanguard

Clinical Development

Understand clinical trials, development strategy and regulatory pathways shaping drug approval.

Content type

Insights
Interviews

Tags

Filters

Type at least 2 characters to search

Showing results for

Content
Experts
Industry partners

Read What 13 Years of Data Shows About Drug Innovation in Psychiatry

Nicole Dale

What 13 Years of Data Shows About Drug Innovation in Psychiatry

From 2012 through 2024, the FDA only approved 22 drugs for the treatment of psychiatric conditions. Pharma R&D teams must rethink development strategies to unstall drug innovation in psychiatry

Drug Discovery

Read Drug Discovery and Pharmacoinformatics in 2026

Nicole Dale

Drug Discovery and Pharmacoinformatics in 2026

Pharmacoinformatics is redefining drug discovery strategy. This analysis covers the AI platforms, molecular design tools, and regulatory frameworks shaping R&D pipelines in 2026.

Drug Discovery

Read Why Precision Alone Isn't Enough in Oncology Drug Discovery

Nicole Dale

Why Precision Alone Isn't Enough in Oncology Drug Discovery

Precision alone isn’t enough in oncology drug discovery. See why execution, biomarkers, and trial design determine scalable success in precision medicine.

Drug Discovery

Read Phenotypic Drug Discovery: Beyond the Target

Nicole Dale

Phenotypic Drug Discovery: Beyond the Target

Phenotypic drug discovery is reshaping how pharma finds first-in-class drugs. This analysis covers the methods, AI integration, and strategic decisions R&D leaders face in 2026.

Drug Discovery

Read Great Drug Discovery Starts with Great Scientists

Nicole Dale

Great Drug Discovery Starts with Great Scientists

Pharmatica image of a modern pharmaceutical research laboratory representing drug discovery scientists using computational biology, structural biology, medicinal chemistry, and AI-assisted therapeutic research.

Learn how drug discovery scientists are evolving alongside AI, computational biology, and multidisciplinary research to accelerate therapeutic innovation.

Drug Discovery

Read FDA 2026 Draft Guidance on Alternatives to Animal Testing

Nicole Dale

FDA 2026 Draft Guidance on Alternatives to Animal Testing

Illustration representing FDA alternatives to animal testing, featuring laboratory research, organ-on-chip technology, genetic science, AI-enabled drug discovery and next-generation pharmaceutical testing methods.

The FDA's March 2026 draft guidance on alternatives to animal testing marks a pivotal shift in preclinical drug development. Here's what pharma R&D teams need to know.

Preclinical Development

Load more

Search

Tags

Search

Search

No result found for

Get Started

Sign in with LinkedIn

Sign in with Google

or

Individual

Access trusted pharma insights for free
Discover actionable analysis from industry experts
Network with pharma professionals across R&D, clinical and regulatory
Unlock exclusive analyst-led interviews and reports
Share your perspective with our global pharma community

Business

Coming Soon…

Access expert pharma resources for your team
Network with professionals and industry leaders
Gain exclusive insights from a global pharma community

Username or email address

Password

Forgot your password?

Sign up with LinkedIn

Sign up with Google

Already have an account?

Privacy Policy
Contact us

Pharmatica — home

Evidence-led pharmaceutical analysis covering drug discovery, clinical development, regulatory policy and industry innovation, designed for professionals shaping the future of life sciences.

Pharmatica on LinkedIn
Pharmatica on YouTube

Topics

Therapeutic Drug Discovery
Clinical Development
Technical Operations
HealthTech & AI

Resources

Insights
Interviews

Network

Scientific Council

Company

About
Sentinel
Vanguard
FAQ

Subscribe to our newsletter

Name

Email

Contact us
Privacy policy
Editorial policy
GDPR policy
Sitemap

All rights reserved. © 2026 | Pharmatica